A new residential program for non-violent women offenders launched today.TheAbout Face Women’s Offender Program, a ...

The issue becomes even more concerning in high-stakes domains. The study identifies a spectrum of risk levels, ranging from ...

CYBERJAYA, MALAYSIA – Media OutReach Newswire – 15 April 2025 - Cerebrill, dedicated to supporting cognitive health and development, recently co-organised the DPulze Cerebrill Aidilfitri FIDE Rated ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild ...

The European Commission has granted marketing authorisation for Leqembi (lecanemab), making it the first therapy in the EU to slow the progression of early Alzheimer’s disease.

RAs, might offer new ways to reduce dementia risk. Discover the latest research and what it means for Alzheimer's treatment.

Individuals with a genetic predisposition to Alzheimer's disease show altered blood levels indicating damaged neuronal contacts as early as 11 years before the expected onset of dementia symptoms.

Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has been approved by the European Commission (EC). The ...

Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD's Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) ...

Discover an activity that sparks creativity, promotes exercise, and forges social connections, helping retirees overcome ...

UNIONDALE, NY / ACCESS Newswire / April 15, 2025 / Amita Khare, LMFT, has been recognized by Marquis Who's Who for her leadership in mental health and community advocacy. Ms. Khare is the founder and ...